ULURU Inc. Announces The Expansion Of The International Marketing
Network
ADDISON, Texas, Oct. 9, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR), today announced the further expansion of the
Altrazeal? international marketing network to include
Croatia, Slovenia, Serbia, Montenegro, Macedonia, Bosnia, Kosovo and Albania.
Marketing and distribution agreements have been signed for this
territory for the exclusive marketing and distribution of
Altrazeal?. It is anticipated that Altrazeal?
will be launched in these markets in the fourth quarter 2013.
Commenting on the extension of the international marketing
network, Helmut Kerschbaumer,
Managing Director of Altrazeal GmbH, stated, "The appointment of an
exclusive marketing partner for this region is in line with our
objective of marketing Altrazeal? throughout the
territory. Collectively there are over 23 million people in this
group of countries which presents an opportunity to generate quite
significant incremental revenue. Marketing activities have
commenced in preparation for the launch of
Altrazeal?."
Altrazeal? is a scientifically engineered advanced
wound dressing designed to incorporate the desired features and
benefits of the ideal wound dressing. Altrazeal?
competes in the advanced wound dressing market which, worldwide, is
estimated to be $6.5 billion growing
annually at 13%. Altrazeal? has demonstrated potential
clinical and economic advantages in a number of chronic and acute
wounds including diabetic foot ulcers, venous leg ulcers and
geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of
wound management and oral care products to provide patients and
consumers improved clinical outcomes through controlled delivery
utilizing its innovative Nanoflex? Aggregate technology
and OraDisc? transmucosal delivery system.? For further information
about ULURU Inc., please visit our website at www.ULURUinc.com.?
For further information about Altrazeal?, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended.? These statements are subject to numerous
risks and uncertainties, including but not limited to the launch of
Altrazeal? in the territory, the commercial
potential of Altrazeal? and the demonstration of cost
savings and clinical benefits, and the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2012, and other reports
filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.